StemRIM Inc
TSE:4599
Intrinsic Value
StemRIM, Inc. engages in the research and development of regeneration inducing medicine. [ Read More ]
The intrinsic value of one StemRIM Inc stock under the Base Case scenario is 127.44 JPY. Compared to the current market price of 443 JPY, StemRIM Inc is Overvalued by 71%.
Valuation Backtest
StemRIM Inc
Run backtest to discover the historical profit from buying and selling StemRIM Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
StemRIM Inc
Current Assets | 9.8B |
Cash & Short-Term Investments | 9.2B |
Other Current Assets | 643.8m |
Non-Current Assets | 232.5m |
PP&E | 205.3m |
Intangibles | 2.9m |
Other Non-Current Assets | 24.3m |
Current Liabilities | 124.1m |
Accrued Liabilities | 23.4m |
Other Current Liabilities | 100.8m |
Non-Current Liabilities | 118.6m |
Other Non-Current Liabilities | 118.6m |
Earnings Waterfall
StemRIM Inc
Revenue
|
2.4B
JPY
|
Operating Expenses
|
-2.2B
JPY
|
Operating Income
|
150.8m
JPY
|
Other Expenses
|
28.6m
JPY
|
Net Income
|
179.4m
JPY
|
Free Cash Flow Analysis
StemRIM Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
StemRIM Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
StemRIM Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
StemRIM Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Score
StemRIM Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
StemRIM Inc
According to Wall Street analysts, the average 1-year price target for StemRIM Inc is 918 JPY with a low forecast of 909 JPY and a high forecast of 945 JPY.
Shareholder Return
Price
StemRIM Inc
Average Annual Return | 0.4% |
Standard Deviation of Annual Returns | 27.79% |
Max Drawdown | -73% |
Market Capitalization | 27.2B JPY |
Shares Outstanding | 61 469 700 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 46 full-time employees. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Contact
IPO
Employees
Officers
The intrinsic value of one StemRIM Inc stock under the Base Case scenario is 127.44 JPY.
Compared to the current market price of 443 JPY, StemRIM Inc is Overvalued by 71%.